Effects of zinc finger protein 403 on the proliferation, migration and invasion abilities of prostate cancer cells

Xu,Xintong; Zhu,Zhihui; Xu,Yipeng; Tian,Shasha; Jiang,Yingjun; Zhao,Huajun

doi:10.3892/or.2020.7786

Effects of zinc finger protein 403 on the proliferation, migration and invasion abilities of prostate cancer cells

Authors:
- Xintong Xu
- Zhihui Zhu
- Yipeng Xu
- Shasha Tian
- Yingjun Jiang
- Huajun Zhao
View Affiliations

Affiliations: College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 311402, P.R. China, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China
Published online on: October 1, 2020 https://doi.org/10.3892/or.2020.7786
Pages: 2455-2464
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Zinc finger protein 403 (ZFP403), located on human chromosome 17q12‑21, is closely associated with the development of cancer. However, to date, there are a limited number of studies on the biological functions of this gene, particularly in prostate cancer (PCa). The results of the present study demonstrated that compared with normal tissues, the expression of ZFP403 was markedly lower in PCa tissues, as shown by the evaluation of the Gene Expression Profiling Interactive Analysis 2 database. The decreased expression of ZFP403 in PCa clinical tissues and cell lines was confirmed by immunohistochemistry, reverse transcription‑quantitative PCR and western blot analysis. Using short harpin (sh)RNA inhibition, stably‑silenced ZFP403 cell lines were then constructed by lentiviral transfection (LV‑PC3‑shRNA‑1 and 2; LV‑DU145‑shRNA‑1 and 2). The results revealed that the knockdown of ZFP403 in PCa cells promoted cellular proliferation, colony formation, migration and invasiveness in vitro. Moreover, the levels of tumor growth‑ and motility‑related proteins were significantly altered after ZFP403‑knockdown. A xenograft tumor model using nude mice was established to elucidate the role of ZFP403 in tumorigenesis in vivo. Tumor growth was significantly increased in mice injected with ZFP403‑knockdown cells compared with the control mice. Overall, the findings of the present study demonstrate that ZFP403 functions as a tumor suppressor gene in PCa by affecting the proliferation, migration and invasiveness of PCa cells, suggesting its potential use as a clinical diagnostic marker.

View Figures

View References

1	Vlaeminck-Guillem V, Gillet G and Rimokh R: SRC: Marker or actor in prostate cancer aggressiveness. Front Oncol. 4:2222014. View Article : Google Scholar : PubMed/NCBI
2	Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P and de Bono JS: Drug discovery in advanced prostate cancer: Translating biology into therapy. Nat Rev Drug Discov. 15:699–718. 2016. View Article : Google Scholar : PubMed/NCBI
3	Nevedomskaya E, Baumgart SJ and Haendler B: Recent advances in prostate cancer treatment and drug discovery. Int J Mol Sci. 19:13592018. View Article : Google Scholar
4	Haymart MR, Miller DC and Hawley ST: Active surveillance for low-risk cancers-a viable solution to overtreatment? N Engl J Med. 377:203–206. 2017. View Article : Google Scholar : PubMed/NCBI
5	Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ and Klotz L: Androgen-targeted therapy in men with prostate cancer: Evolving practice and future considerations. Prostate Cancer Prostatic Dis. 22:24–38. 2019. View Article : Google Scholar : PubMed/NCBI
6	Pan TF, Liang CZ, Chen XG and Fan S: Mammalian target of rapamycin regulates androgen receptor and Akt phosphorylation in prostate cancer 22RV1 cells. Zhonghua Nan Ke Xue. 19:1068–1071. 2013.(In Chinese). PubMed/NCBI
7	Sumanasuriya S and De Bono J: Treatment of advanced prostate cancer-a review of current therapies and future promise. Cold Spring Harb Perspect Med. 8:a0306352018. View Article : Google Scholar : PubMed/NCBI
8	Wu CT, Chen WC and Chen MF: The response of prostate cancer to androgen deprivation and irradiation due to immune modulation. Cancers (Basel). 11:202018. View Article : Google Scholar
9	Lan ZJ, Hu YH, Zhang S, Li X, Zhou H, Ding J, Klinge CM, Radde BN, Cooney AJ, Zhang J and Lei Z: GGNBP2 acts as a tumor suppressor by inhibiting estrogen receptor α activity in breast cancer cells. Breast Cancer Res Treat. 158:263–276. 2016. View Article : Google Scholar : PubMed/NCBI
10	Guan R, Wen XY, Wu J, Duan R, Cao H, Lam S, Hou D, Wang Y, Hu J and Chen Z: Knockdown of ZNF403 inhibits cell proliferation and induces G2/M arrest by modulating cell-cycle mediators. Mol Cell Biochem. 365:211–222. 2012. View Article : Google Scholar : PubMed/NCBI
11	Zhang J, Wang Y, Zhou Y, Cao Z, Huang P and Lu B: Yeast two-hybrid screens imply that GGNBP1, GGNBP2 and OAZ3 are potential interaction partners of testicular germ cell-specific protein GGN1. FEBS Lett. 579:559–566. 2005. View Article : Google Scholar : PubMed/NCBI
12	Li Y and Chen Z: Molecular cloning and characterization of LCRG1 a novel gene localized to the tumor suppressor locus D17S800-D17S930. Cancer Lett. 209:75–85. 2004. View Article : Google Scholar : PubMed/NCBI
13	Plummer SJ, Paris MJ, Myles J, Tubbs R, Crowe J and Casey G: Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors. Genes Chromosomes Cancer. 20:354–362. 1997. View Article : Google Scholar : PubMed/NCBI
14	Zhu Z, Lou C, Zheng Z, Zhu R, Tian S, Xie C and Zhao H: ZFP403, a novel tumor suppressor, inhibits the proliferation and metastasis in ovarian cancer. Gynecol Oncol. 147:418–425. 2017. View Article : Google Scholar : PubMed/NCBI
15	Zhan A, Lei B, Wu H, Wen YT, Zheng L, Wang S, Wan X and Wei Z: GGNBP2 suppresses the proliferation, invasion, and migration of human glioma cells. Oncol Res. 25:831–842. 2017. View Article : Google Scholar : PubMed/NCBI
16	Guo K, He Y, Liu L, Liang Z, Li X, Cai L, Lan ZJ, Zhou J, Wang H and Lei Z: Ablation of Ggnbp2 impairs meiotic DNA double-strand break repair during spermatogenesis in mice. J Cell Mol Med. 22:4863–4874. 2018. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Yang B, Zhao Y, Lou C and Zhao H: Eupalinolide O, a novel sesquiterpene lactone from eupatorium lindleyanum DC., induces cell cycle arrest and apoptosis in human MDA-MB-468 breast cancer cells. Oncol Rep. 36:2807–2813. 2016. View Article : Google Scholar : PubMed/NCBI
19	Tian SS, Chen Y, Yang B, Lou C, Zhu R, Zhao Y and Zhao H: F1012-2 inhibits the growth of triple negative breast cancer through induction of cell cycle arrest, apoptosis, and autophagy. Phytother Res. 32:908–922. 2018. View Article : Google Scholar : PubMed/NCBI
20	Li LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou X, Zhang ZJ, Peng YH, Yang YZ and Yun JP: miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. Carcinogenesis. 35:469–478. 2014. View Article : Google Scholar : PubMed/NCBI
21	Yang B, Zhu R, Tian S, Wang Y, Lou S and Zhao H: Jatamanvaltrate P induces cell cycle arrest, apoptosis and autophagy in human breast cancer cells in vitro and in vivo. Biomed Pharmacother. 89:1027–1036. 2017. View Article : Google Scholar : PubMed/NCBI
22	Baade PD, Youlden DR and Krnjacki LJ: International epidemiology of prostate cancer: Geographical distribution and secular trends. Mol Nutr Food Res. 53:171–184. 2009. View Article : Google Scholar : PubMed/NCBI
23	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
24	Chang AJ, Autio KA, Roach M III and Scher HI: High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 11:308–323. 2014. View Article : Google Scholar : PubMed/NCBI
25	Miyamoto H, Messing EM and Chang C: Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate. 61:332–353. 2004. View Article : Google Scholar : PubMed/NCBI
26	Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A and Kubota Y: Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther. 2:1139–1147. 2003.PubMed/NCBI
27	Li J, Luo J, Gu D, Jie F, Pei N, Li A, Chen X, Zhang Y, Du H, Chen B, et al: Adenovirus-mediated angiotensin II type 2 receptor overexpression inhibits tumor growth of prostate cancer in vivo. J Cancer. 7:184–191. 2016. View Article : Google Scholar : PubMed/NCBI
28	Walsh PC, DeWeese TL and Eisenberger MA: Clinical practice. Localized prostate cancer. N Engl J Med. 357:2696–2705. 2007. View Article : Google Scholar : PubMed/NCBI
29	Bommareddy A, Rule B, VanWert AL, Santha S and Dwivedi C: α-Santalol, a derivative of sandalwood oil, induces apoptosis in human prostate cancer cells by causing caspase-3 activation. Phytomedicine. 19:804–811. 2012. View Article : Google Scholar : PubMed/NCBI
30	Wirth T and Ylä-Herttuala S: Gene therapy used in cancer treatment. Biomedicines. 2:149–162. 2014. View Article : Google Scholar : PubMed/NCBI
31	Workman P: New drug targets for genomic cancer therapy: Successes, limitations, opportunities and future challenges. Curr Cancer Drug Targets. 1:33–47. 2001. View Article : Google Scholar : PubMed/NCBI
32	Saraon P, Musrap N, Cretu D, Karagiannis GS, Batruch I, Smith C, Drabovich AP, Trudel D, van der Kwast T, Morrissey C, et al: Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer. J Biol Chem. 287:34019–34031. 2012. View Article : Google Scholar : PubMed/NCBI
33	Ozen M and Ittmann M: Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin Cancer Res. 11:4701–4706. 2005. View Article : Google Scholar : PubMed/NCBI
34	Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ and Dutta A: Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res. 56:4159–4163. 1996.PubMed/NCBI
35	Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman RP Jr, Muraca PJ and Ross JS: Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol. 16:1302–1309. 1998. View Article : Google Scholar : PubMed/NCBI
36	Maddison LA, Huss WJ, Barrios RM and Greenberg NM: Differential expression of cell cycle regulatory molecules and evidence for a ‘cyclin switch’ during progression of prostate cancer. Prostate. 58:335–344. 2004. View Article : Google Scholar : PubMed/NCBI
37	Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, et al: Initial sequencing and analysis of the human genome. Nature. 409:860–921. 2001. View Article : Google Scholar : PubMed/NCBI
38	Tupler R, Perini G and Green MR: Expressing the human genome. Nature. 409:832–833. 2001. View Article : Google Scholar : PubMed/NCBI
39	Jen JY and Wang YC: Zinc finger proteins in cancer progression. J Biomed Sci. 23:532016. View Article : Google Scholar : PubMed/NCBI
40	Cassandri M, Smirnov A, Novelli F, Pitolli C, Agostini M, Malewicz M, Melino G and Raschellà G: Zinc-finger proteins in health and disease. Cell Death Discov. 3:170172017. View Article : Google Scholar : PubMed/NCBI
41	Clarke NW, Hart CA and Brown MD: Molecular mechanisms of metastasis in prostate cancer. Asian J Androl. 11:57–67. 2009. View Article : Google Scholar : PubMed/NCBI
42	Chen HN, Yuan K, Xie N, Wang K, Huang Z, Chen Y, Dou Q, Wu M, Nice EC, Zhou ZG and Huang C: PDLIM1 stabilizes the E-Cadherin/β-catenin complex to prevent epithelial-mesenchymal transition and metastatic potential of colorectal cancer cells. Cancer Res. 76:1122–1134. 2016. View Article : Google Scholar : PubMed/NCBI
43	Yang Z, Wang Y and Ma L: Effects of gametogenetin-binding protein 2 on proliferation, invasion and migration of prostate cancer PC-3 cells. Andrologia. 52:e134882020. View Article : Google Scholar : PubMed/NCBI